Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Dynavax Technologies Corporation (DVAX - Snapshot Report) reported a loss of 9 cents per share in the third quarter of 2013, in line with the Zacks Consensus Estimate, but narrowed from the year-ago loss of 10 cents per share.

Dynavax reported revenues of $2.9 million, up 1.8% from the year-ago period and surpassing the Zacks Consensus Estimate of $2 million.

Collaboration revenues came in at $1.1 million, up 5.7% from the year-ago quarter.

Grant revenue from Dynavax contract for adjuvant development awarded by the National Institutes of Health grew 39.4% to $1.7 million from the year-ago quarter.

Research and development expenses declined 8.4% to $11.8 million in the third quarter of 2013. General and administrative expenses declined 18.4% to $5.8 million.

We remind investors that Dynavax is developing a hepatitis B vaccine for adults – Heplisav, which is currently under review in the U.S. and Europe.

Last month, Dynavax received encouraging news when the design of its next large-scale clinical study on Heplisav, was finalized following discussions with the U.S. Food and Drug Administration (FDA).

We note that Dynavax suffered a setback in Jun 2013 when the FDA asked for additional safety data on Heplisav. The company had conducted a meeting with the agency to discuss the complete response letter (CRL) received earlier this year for the Heplisav Biologic License Application (BLA).

The FDA had then stated that the database needed additional subjects as analyzing the safety profile on the current database would probably lead to an approval for a limited population, thereby preventing additional patients to benefit from the treatment, if approved.

Apart from Heplisav, Dynavax is also developing AZD1419, for the treatment of asthma, in partnership with AstraZeneca (AZN - Analyst Report) and DV1179 (autoimmune and inflammatory diseases) with GlaxoSmithKline (GSK - Analyst Report).

The third quarter results did not surprise us. We expect investor focus to remain on Heplisav updates.

Dynavax carries a Zacks Rank #4 (Sell). Right now, Actelion Ltd. (ALIOF) looks well placed with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
MODINE MANUF MOD 17.43 +10.74%
VERTEX ENERG VTNR 8.10 +8.59%
KNIGHTSBRIDG VLCCF 13.24 +5.54%
E*TRADE FINA ETFC 22.69 +5.51%
CANADIAN SOL CSIQ 30.69 +5.07%